Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Neeraj Mishra; Sumel Ashique; Ashish Garg; Vineet Kumar Rai; Kamal Dua; Amit Goyal; Shvetank Bhatt

doi:10.1016/j.drudis.2022.01.003

Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Drug Discov Today. 2022 May;27(5):1431-1440. doi: 10.1016/j.drudis.2022.01.003. Epub 2022 Jan 10.

Authors

Neeraj Mishra¹, Sumel Ashique², Ashish Garg³, Vineet Kumar Rai⁴, Kamal Dua⁵, Amit Goyal⁶, Shvetank Bhatt⁷

Affiliations

¹ Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, MP 474005, India.
² Department of Pharmaceutics, Bharat Institute of Technology (BIT), BIT-School of Pharmacy, Meerut, UP 250103, India.
³ Department of P.G. Studies and Research in Chemistry and Pharmacy, Rani Durgavati University, Jabalpur, MP 482001, India.
⁴ Department of Pharmaceutics, ISF College of Pharmacy, Ghal Kalan, Moga, Punjab 142001, India.
⁵ Discipline of Pharmacy Graduate School of Health, University of Technology Sydney, Ultimo 2007, NSW, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo 2007, NSW, Australia.
⁶ Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, India.
⁷ Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, MP 474005, India. Electronic address: [email protected].

PMID: 35017085
DOI: 10.1016/j.drudis.2022.01.003

Abstract

Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

Keywords: Liposomes; Nanoparticles; Nanostructured lipid carriers; Neurodegenerative disorders; Small interfering RNA; Solid lipid nanoparticle.

Publication types

Review

MeSH terms

Drug Carriers / chemistry
Humans
Nanoparticles* / chemistry
Nanotechnology
Neurodegenerative Diseases* / drug therapy
Neurodegenerative Diseases* / genetics
RNA, Small Interfering

Substances

Drug Carriers
RNA, Small Interfering